Mather Group, Llc. Immuno Gen, Inc. Transaction History
Mather Group, Llc.
- $6.64 Billion
- Q1 2024
A detailed history of Mather Group, Llc. transactions in Immuno Gen, Inc. stock. As of the latest transaction made, Mather Group, Llc. holds 62 shares of IMGN stock, worth $0. This represents 0.0% of its overall portfolio holdings.
Number of Shares
62Holding current value
$0% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding IMGN
# of Institutions
13Shares Held
1.41MCall Options Held
0Put Options Held
0-
Pictet Asset Management Sa Geneva 73, V8721KShares$00.02% of portfolio
-
Decheng Capital Management Iii (Cayman), LLC416KShares$03.65% of portfolio
-
Health Cor Management, L.P. New York, NY150KShares$00.7% of portfolio
-
Kellner Capital, LLC New York, NY69.2KShares$03.7% of portfolio
-
Leo Brokerage, LLC25KShares$00.05% of portfolio
About ImmunoGen, Inc.
- Ticker IMGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 220,712,992
- Description
- ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...